Can anti-IgE therapy prevent airway remodeling in allergic asthma?

K. F. Rabe, William Calhoun, N. Smith, P. Jimenez

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Airway remodeling is a central feature of asthma. It is exemplified by thickening of the lamina reticularis and structural changes to the epithelium, submucosa, smooth muscle, and vasculature of the airway wall. Airway remodeling may result from persistent airway inflammation. Immunoglobulin E (IgE) is an important mediator of allergic reactions and has a central role in airway inflammation and asthma-related symptoms. Anti-IgE therapies (such as omalizumab) have the potential to block an early step in the allergic cascade and therefore have the potential to reduce airway remodeling. The reduction in free IgE levels following anti-IgE therapy leads to reductions in high-affinity IgE receptor (Fc∈RI) expression on mast cells, basophils, and dendritic cells. This combined effect results in attenuation of several markers of inflammation, including peripheral and bronchial tissue eosinophilia and levels of granulocyte macrophage colony-stimulating factor, interleukin (IL)-2, IL-4, IL-5, and IL-13. Considering the previously demonstrated anti-inflammatory effects of anti-IgE therapy, along with results from a small study showing continued benefit after discontinuation of long-term treatment, a larger study to assess its effect on markers of airway remodeling is underway.

Original languageEnglish (US)
Pages (from-to)1142-1151
Number of pages10
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume66
Issue number9
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Airway Remodeling
Passive Immunization
Immunoglobulin E
Asthma
Granulocyte-Macrophage Colony-Stimulating Factor
Inflammation
IgE Receptors
Interleukin-13
Basophils
Interleukin-5
Eosinophilia
Mast Cells
Interleukin-4
Dendritic Cells
Interleukin-2
Smooth Muscle
Hypersensitivity
Anti-Inflammatory Agents
Epithelium
Distance Counseling

Keywords

  • airway remodeling
  • allergic asthma
  • anti-IgE
  • omalizumab

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Can anti-IgE therapy prevent airway remodeling in allergic asthma? / Rabe, K. F.; Calhoun, William; Smith, N.; Jimenez, P.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 66, No. 9, 09.2011, p. 1142-1151.

Research output: Contribution to journalArticle

@article{88f83b1ac03c495eac549b8e5b23c313,
title = "Can anti-IgE therapy prevent airway remodeling in allergic asthma?",
abstract = "Airway remodeling is a central feature of asthma. It is exemplified by thickening of the lamina reticularis and structural changes to the epithelium, submucosa, smooth muscle, and vasculature of the airway wall. Airway remodeling may result from persistent airway inflammation. Immunoglobulin E (IgE) is an important mediator of allergic reactions and has a central role in airway inflammation and asthma-related symptoms. Anti-IgE therapies (such as omalizumab) have the potential to block an early step in the allergic cascade and therefore have the potential to reduce airway remodeling. The reduction in free IgE levels following anti-IgE therapy leads to reductions in high-affinity IgE receptor (Fc∈RI) expression on mast cells, basophils, and dendritic cells. This combined effect results in attenuation of several markers of inflammation, including peripheral and bronchial tissue eosinophilia and levels of granulocyte macrophage colony-stimulating factor, interleukin (IL)-2, IL-4, IL-5, and IL-13. Considering the previously demonstrated anti-inflammatory effects of anti-IgE therapy, along with results from a small study showing continued benefit after discontinuation of long-term treatment, a larger study to assess its effect on markers of airway remodeling is underway.",
keywords = "airway remodeling, allergic asthma, anti-IgE, omalizumab",
author = "Rabe, {K. F.} and William Calhoun and N. Smith and P. Jimenez",
year = "2011",
month = "9",
doi = "10.1111/j.1398-9995.2011.02617.x",
language = "English (US)",
volume = "66",
pages = "1142--1151",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Can anti-IgE therapy prevent airway remodeling in allergic asthma?

AU - Rabe, K. F.

AU - Calhoun, William

AU - Smith, N.

AU - Jimenez, P.

PY - 2011/9

Y1 - 2011/9

N2 - Airway remodeling is a central feature of asthma. It is exemplified by thickening of the lamina reticularis and structural changes to the epithelium, submucosa, smooth muscle, and vasculature of the airway wall. Airway remodeling may result from persistent airway inflammation. Immunoglobulin E (IgE) is an important mediator of allergic reactions and has a central role in airway inflammation and asthma-related symptoms. Anti-IgE therapies (such as omalizumab) have the potential to block an early step in the allergic cascade and therefore have the potential to reduce airway remodeling. The reduction in free IgE levels following anti-IgE therapy leads to reductions in high-affinity IgE receptor (Fc∈RI) expression on mast cells, basophils, and dendritic cells. This combined effect results in attenuation of several markers of inflammation, including peripheral and bronchial tissue eosinophilia and levels of granulocyte macrophage colony-stimulating factor, interleukin (IL)-2, IL-4, IL-5, and IL-13. Considering the previously demonstrated anti-inflammatory effects of anti-IgE therapy, along with results from a small study showing continued benefit after discontinuation of long-term treatment, a larger study to assess its effect on markers of airway remodeling is underway.

AB - Airway remodeling is a central feature of asthma. It is exemplified by thickening of the lamina reticularis and structural changes to the epithelium, submucosa, smooth muscle, and vasculature of the airway wall. Airway remodeling may result from persistent airway inflammation. Immunoglobulin E (IgE) is an important mediator of allergic reactions and has a central role in airway inflammation and asthma-related symptoms. Anti-IgE therapies (such as omalizumab) have the potential to block an early step in the allergic cascade and therefore have the potential to reduce airway remodeling. The reduction in free IgE levels following anti-IgE therapy leads to reductions in high-affinity IgE receptor (Fc∈RI) expression on mast cells, basophils, and dendritic cells. This combined effect results in attenuation of several markers of inflammation, including peripheral and bronchial tissue eosinophilia and levels of granulocyte macrophage colony-stimulating factor, interleukin (IL)-2, IL-4, IL-5, and IL-13. Considering the previously demonstrated anti-inflammatory effects of anti-IgE therapy, along with results from a small study showing continued benefit after discontinuation of long-term treatment, a larger study to assess its effect on markers of airway remodeling is underway.

KW - airway remodeling

KW - allergic asthma

KW - anti-IgE

KW - omalizumab

UR - http://www.scopus.com/inward/record.url?scp=79961127439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961127439&partnerID=8YFLogxK

U2 - 10.1111/j.1398-9995.2011.02617.x

DO - 10.1111/j.1398-9995.2011.02617.x

M3 - Article

VL - 66

SP - 1142

EP - 1151

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 9

ER -